AMENDMENTS TO THE CLAIMS

The claims in this listing will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-16 (Canceled)

Claim 17 (New). A medicament for preventive and/or therapeutic treatment of dermal pigmentation and/or development of skin cancer, which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof:

wherein X represents a group represented by the following formula:

wherein a bond at the left end binds to ring Z and a bond at the right end binds to E, A represents hydrogen atom,

E represents a 2,5-di-substituted phenyl group wherein at least one of said substituents is trifluoromethyl group, a 3,5-di-substituted phenyl group wherein at least one of said substituents is trifluoromethyl group, or a 4,5-di-substituted thiazol-2-yl group,

ring Z represents a C₆ to C₁₀ arene which may have one or more substituents in addition to the group represented by formula —O—A wherein A has the same meaning as that defined above and the group represented by formula —X—E wherein each of X and E has the same meaning as that defined above, or a 5- to 13-membered heteroarene which may have one or more substituents in addition to the group represented by formula —O—A wherein A has the same meaning as that defined above and the group represented by formula —X—E wherein each of X and E has the same meaning as that defined above.

Claim 18 (New). The medicament according to claim 17, wherein E is a group selected from the group consisting of the following substituent group δ -3e, substituent group δ -5e, and substituent group δ -8e,

the following partial formula (Iz-1) in the general formula (I) containing ring Z

is the following formula (Iz-2):

wherein R^z represents a group selected from the following substituent group γ -2z. [Substituent Group δ -3e] 2-chloro-5-(trifluoromethyl)phenyl group, 2,5-bis(trifluoromethyl)phenyl group, 2-fluoro-5-(trifluoromethyl)phenyl group, 2-nitro-5-

(trifluoromethyl)phenyl group, 2-methyl-5-(trifluoromethyl)phenyl group, 2-methoxy-5-(trifluoromethyl)phenyl group, 2-methylsulfanyl-5-(trifluoromethyl)phenyl group, 2-(1pyrrolidinyl)-5-(trifluoromethyl)phenyl group, 2-morpholino-5-(trifluoromethyl)phenyl group, 2-bromo-5-(trifluoromethyl)phenyl group, 2-(2-naphthyloxy)-5-(trifluoromethyl)phenyl group, 2-(2,4-dichlorophenoxy)-5-(trifluoromethyl)phenyl group, 2-[4-(trifluoromethyl)piperidin-1-yl]-5-(trifluoromethyl)phenyl group, 2-(2,2,2trifluoroethoxy)-5-(trifluoromethyl)phenyl group, 2-(2-methoxyphenoxy)-5-(trifluoromethyl)phenyl group, 2-(4-chloro-3,5-dimethylphenoxy)-5-(trifluoromethyl)phenyl group, 2-piperidino-5-(trifluoromethyl)phenyl group, 2-(4methylphenoxy)-5-(trifluoromethyl)phenyl group, 2-(4-chlorophenoxy)-5-(trifluoromethyl)phenyl group, 2-(4-cyanophenoxy)-5-(trifluoromethyl)phenyl group, 2-(4methoxyphenoxy)-5-(trifluoromethyl)phenyl group [Substituent Group δ-5e] 3,5-bis(trifluoromethyl)phenyl group, 3-fluoro-5-(trifluoromethyl)phenyl group, 3-bromo-5-(trifluoromethyl)phenyl group, 3-methoxy-5-(trifluoromethyl)phenyl group, 3-methoxycarbonyl-5-(trifluoromethyl)phenyl group, 3carboxy-5-(trifluoromethyl)phenyl group [Substituent Group δ-8e] 5-bromo-4-[(1,1-dimethyl)ethyl]thiazol-2-yl group, 5-bromo-4-(trifluoromethyl)thiazol-2-yl group, 5-cyano-4-[(1,1-dimethyl)ethyl]thiazol-2-yl group, 4,5dimethylthiazol-2-yl group, 5-methyl-4-phenylthiazol-2-yl group, 5-(4-fluorophenyl)-4methylthiazol-2-yl group, 4-methyl-5-[3-(trifluoromethyl)phenyl]thiazol-2-yl group, 4-[(1,1-dimethyl)ethyl]-5-ethylthiazol-2-yl group, 4-ethyl-5-phenylthiazol-2-yl group, 4isopropyl-5-phenylthiazol-2-yl group, 4-butyl-5-phenylthiazol-2-yl group, 4-[(1,1dimethyl)ethyl]-5-[(2,2-dimethyl)propionyl]thiazol-2-yl group, 4-[(1,1-dimethyl)ethyl]-5-

(ethoxycarbonyl)thiazol-2-yl group, 4-[(1,1-dimethyl)ethyl]-5-piperidinothiazol-2-yl group, 4-[(1,1-dimethyl)ethyl]-5-morpholinothiazol-2-yl group, 4-[(1,1-dimethyl)ethyl]-5-(4methylpiperazin-1-yl)thiazol-2-yl group, 4-[(1,1-dimethyl)ethyl]-5-(4-phenylpiperazin-1yl)thiazol-2-yl group, 5-carboxymethyl-4-phenylthiazol-2-yl group, 4,5-diphenylthiazol-2yl group, 4-benzyl-5-phenylthiazol-2-yl group, 5-phenyl-4-(trifluoromethyl)thiazol-2-yl group, 5-acetyl-4-phenylthiazol-2-yl group, 5-benzoyl-4-phenylthiazol-2-yl group, 5ethoxycarbonyl-4-phenylthiazol-2-yl group, 5-ethoxycarbonyl-4-(pentafluorophenyl)thiazol-2-yl group, 5-methylcarbamoyl-4-phenylthiazol-2-yl group, 5ethylcarbamoyl-4-phenylthiazol-2-yl group, 5-isopropylcarbamoyl-4-phenylthiazol-2-yl group, 5-(2-phenylethyl)carbamoyl-4-phenylthiazol-2-yl group, 5-ethoxycarbonyl-4-(trifluoromethyl)thiazol-2-yl group, 5-carboxy-4-[(1,1-dimethyl)ethyl]thiazol-2-yl group, 5-(ethoxycarbonyl)methyl-4-phenylthiazol-2-yl group, 5-carboxy-4-phenylthiazol-2-yl group, 5-propylcarbamoyl-4-phenylthiazol-2-yl group [Substituent Group γ-2z] a halogen atom, nitro group, cyano group, methoxy group, methyl group, isopropyl group, tert-butyl group, 1,1,3,3-tetramethylbutyl group, 2phenylethen-1-yl group, 2,2-dicyanoethen-1-yl group, 2-cyano-2-(methoxycarbonyl)ethen-1-yl group, 2-carboxy-2-cyanoethen-1-yl group, ethynyl group, phenylethynyl group, (trimethylsilyl)ethynyl group, trifluoromethyl group, pentafluoroethyl group, phenyl group, 4-(trifluoromethyl)phenyl group, 4-fluorophenyl group, 2,4difluorophenyl group, 2-phenethyl group, 1-hydroxyethyl group, 1-(methoxyimino)ethyl group, 1-[(benzyloxy)imino]ethyl group, 2-thienyl group, 3-thienyl group, 1-pyrrolyl group, 2-methylthiazol-4-yl group, imidazo[1,2-a]pyridin-2-yl group, 2-pyridyl group, acetyl group, isobutyryl group, piperidinocarbonyl group, 4-benzylpiperidinocarbonyl

group, (pyrrol-1-yl)sulfonyl group, carboxy group, methoxycarbonyl group, N-[3,5-bis(trifluoromethyl)phenyl]carbamoyl group, N,N-dimethylcarbamoyl group, sulfamoyl group, N-[3,5-bis(trifluoromethyl)phenyl]sulfamoyl group, N,N-dimethylsulfamoyl group, amino group, N,N-dimethylamino group, acetylamino group, benzoylamino group, methanesulfonylamino group, benzenesulfonylamino group, 3-phenylureido group, (3-phenyl)thioureido group, (4-nitrophenyl)diazenyl group, {[4-(pyridin-2-yl)sulfamoyl]phenyl}diazenyl group

Claim 19 (New). The medicament according to claim 18, wherein E is a group selected from the group consisting of the aforementioned substituent group δ -3e, substituent group δ -5e, and substituent group δ -8e, and R^z is a halogen atom.

Claim 20 (New). The medicament according to claim 19, wherein E is 2,5-bis(trifluoromethyl)phenyl group or 3,5-bis(trifluoromethyl)phenyl group, and R^z is a halogen atom.

Claim 21 (New). The medicament according to claim 20, wherein E is 3,5-bis(trifluoromethyl)phenyl group, and R^z is a halogen atom.

Claim 22 (New). The medicament according to claim 17, wherein E is 3,5-bis(trifluoromethyl)phenyl group.

Claim 23 (New) The medicament according to claim 17, wherein the following partial formula (Iz-1) in the general formula (I) containing ring Z

is the following formula (Iz-2):

wherein R^z represents a halogen atom.

Claim 24 (New). The medicament according to claim 17, for preventive and/or therapeutic treatment of dermal pigmentation.

Claim 25 (New). The medicament according to claim 21, for preventive and/or therapeutic treatment of dermal pigmentation.

Claim 26 (New). The medicament according to claim 17, having inhibitory activity against transformation and/or proliferation of melanocytes caused by ultraviolet irradiation.

Claim 27 (New). The medicament according to claim 21, having inhibitory activity against transformation and/or proliferation of melanocytes caused by ultraviolet irradiation.

Claim 28 (New). A cosmetic composition which comprises a substance according to claim 17 as an active ingredient having a skin whitening effect.

Claim 29 (New). A cosmetic composition which comprises a substance according to claim 21 as an active ingredient having a skin whitening effect.